+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vectors and Plasmid DNA Manufacturing Market by Product Type and Plasmid, by Application, and by End-User: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018-2026

  • ID: 4853934
  • Report
  • December 2018
  • Region: Global
  • 120 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the viral vectors and plasmid DNA manufacturing market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the viral vectors and plasmid DNA manufacturing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the viral vectors and plasmid DNA manufacturing market on a global level.

In order to give the users of this report a comprehensive view of the viral vectors and plasmid DNA manufacturing market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the viral vectors and plasmid DNA manufacturing market by segmenting the market based on product type, application, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. By product type, the market is segmented into viral vectors and plasmid. The viral vectors are further segmented into a retrovirus, lentiviruses, adenoviruses, adeno-associated viruses, and others. The plasmid segment includes DNA conjugative plasmids and non-conjugative plasmids. By application, the market for viral vectors and plasmid DNA manufacturing is segmented into gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. By end-user, the market is segmented into biotechnology companies, research institutes, hospitals, and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further division into major countries including the U.S., Rest of North America, UK, Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa, and Rest of the Middle East and Africa. This segmentation includes the demand for viral vectors and plasmid DNA manufacturing market based on individual product type, application, and end-user in all the regions and countries.

The report also includes detailed profiles of various end players, such as Vigene Biosciences Inc., Lonza, FinVector Vision Therapies, Kaneka Corporation (Eurogentec), VGXI, Inc., VIROVEK, SIRION Biotech GmbH, Cobra Biologics, Novasep, FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc., Genzyme Corporation, ALDEVRON, Brammer Bio, Oxford Gene Technology, and General Electric Company (GE Healthcare), among others.

This report segments the global viral vectors and plasmid DNA manufacturing market into:

Global Viral Vectors and Plasmid DNA Manufacturing Market: Product Type Analysis

  • Viral Vectors
  • Retrovirus
  • Lentiviruses
  • Adenoviruses
  • Adeno-Associated Viruses
  • Others
  • Plasmids
  • DNA Conjugative Plasmids
  • Non-Conjugative Plasmids

Global Viral Vectors and Plasmid DNA Manufacturing Market: Application Analysis

  • Gene and Cancer Therapies
  • Viral Infections
  • Immunotherapy 
  • Formulation Development
  • Others

Global Viral Vectors and Plasmid DNA Manufacturing Market: End-User Analysis

  • Biopharmaceutical Companies
  • Research Institutes
  • Others?

Global Viral Vectors and Plasmid DNA Manufacturing Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Viral Vectors and Plasmid DNA Manufacturing market, 2016 - 2026 (USD Million)
    • 2.2. Global Viral Vectors and Plasmid DNA Manufacturing market: Snapshot
  • Chapter 3. Viral Vectors and Plasmid DNA Manufacturing Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Viral Vectors and Plasmid DNA Manufacturing market drivers: impact analysis
      • 3.2.2. Surge in global incidence of chronic diseases and increase in geriatric population
      • 3.2.3. Government initiatives & grants and an increase in investments by private companies on R&D activities
    • 3.3. Market Restraints
      • 3.3.1. Global Viral Vectors and Plasmid DNA Manufacturing market restraints: impact analysis
      • 3.3.2. Risk of mutagenesis and other impediments in gene therapy, and high costs associated with gene therapy
    • 3.4. Opportunities
      • 3.4.1. Untapped potential of developing countries provides lucrative opportunities to the market players
    • 3.5. Porter's Five Forces Analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by product type segment
      • 3.6.2. Market attractiveness analysis, by application segment
      • 3.6.3. Market attractiveness analysis, by End-User segment
      • 3.6.4. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Viral Vectors and Plasmid DNA Manufacturing Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Viral Vectors and Plasmid DNA Manufacturing market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Viral Vectors and Plasmid DNA Manufacturing Market- Product Type Segment Analysis
    • 5.1. Global Viral Vectors and Plasmid DNA Manufacturing market: product overview
      • 5.1.1. Global Viral Vectors and Plasmid DNA Manufacturing market revenue share, by product type, 2017 and 2026
    • 5.2. Viral Vectors
      • 5.2.1. Global Viral Vectors Manufacturing market, 2016 - 2026 (USD Million)
      • 5.2.2. Global Viral Vectors Manufacturing market for Retrovirus 2017
      • 5.2.3. Global Viral Vectors market for Lentiviruses 2017
      • 5.2.4. Global Viral Vectors Manufacturing market for Adenoviruses 2017
      • 5.2.5. Global Viral Vectors Manufacturing market for Adeno-Associated Viruses 2017
      • 5.2.6. Global Viral Vectors Manufacturing market for other Viruses 2017
    • 5.3. Plasmid
      • 5.3.1. Global Plasmid DNA Manufacturing market for Plasmid, 2016 - 2026 (USD Million)
      • 5.3.2. Global Plasmid DNA Manufacturing market for DNA Conjugative Plasmids 2017
      • 5.3.3. Global Plasmid DNA Manufacturing market for Non-Conjugative Plasmids 2017
  • Chapter 6. Global Viral Vectors and Plasmid DNA Manufacturing Market - Application Segment Analysis
    • 6.1. Global Viral Vectors and Plasmid DNA Manufacturing market: Application type overview
      • 6.1.1. Global Viral Vectors and Plasmid DNA Manufacturing market revenue share, by Application, 2017 and 2026
    • 6.2. Gene and Cancer Therapies
      • 6.2.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Gene and Cancer Therapies, 2016 - 2026 (USD Million)
    • 6.3. Viral Infections
      • 6.3.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Viral Infections, 2016 - 2026 (USD Million)
    • 6.4. Immunotherapy
      • 6.4.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Immunotherapy,2016 - 2026 (USD Million)
    • 6.5. Formulation Development
      • 6.5.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Formulation Development, 2016 - 2026 (USD Million)
    • 6.6. Other Applications
      • 6.6.1. Global Viral Vectors and Plasmid DNA Manufacturing market for other applications, 2016 - 2026 (USD Million)
  • Chapter 7. Global Viral Vectors and Plasmid DNA Manufacturing Market - End-User Segment Analysis
    • 7.1. Global Viral Vectors and Plasmid DNA Manufacturing market: End-User type overview
      • 7.1.1. Global Viral Vectors and Plasmid DNA Manufacturing market revenue share, by End-User, 2017 and 2026
    • 7.2. Biopharmaceutical Companies
      • 7.2.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Biopharmaceutical Companies, 2016 - 2026 (USD Million)
    • 7.3. Research Institutes
      • 7.3.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Research Institutes, 2016 - 2026 (USD Million)
    • 7.4. Other End-user
      • 7.4.1. Global Viral Vectors and Plasmid DNA Manufacturing market for Other End-user, 2016 - 2026 (USD Million)
  • Chapter 8. Global Viral Vectors and Plasmid DNA Manufacturing Market- Regional Segment Analysis
    • 8.1. Global Viral Vectors and Plasmid DNA Manufacturing market: regional overview
      • 8.1.1. Global Viral Vectors and Plasmid DNA Manufacturing market revenue share, by region, 2017 and 2026
    • 8.2. North America
      • 8.2.1. North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026 (USD Million)
      • 8.2.2. North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026 (USD Million)
      • 8.2.3. North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.2.4.2. The U.S. Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.2.4.3. The U.S. Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.2.5.2. Rest of North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.2.5.3. Rest of North America Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
      • 8.3.2. Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
      • 8.3.3. Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.4. U.K.
        • 8.3.4.1. U.K. Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026 (USD Million)
        • 8.3.4.2. U.K. Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.4.3. U.K. Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.3.5.2. Germany Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.5.3. Germany Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.3.6.2. France Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.6.3. France Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.7. Italy
        • 8.3.7.1. Italy Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.3.7.2. Italy Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.7.3. Italy Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.8. Spain
        • 8.3.8.1. Spain Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.3.8.2. Spain Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.8.3. Spain Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.3.9. Rest of Europe
        • 8.3.9.1. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.3.9.2. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.3.9.3. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026 (USD Million)
      • 8.4.2. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
      • 8.4.3. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.4.4. China
        • 8.4.4.1. ChinaViral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.4.4.2. China Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.4.4.3. China Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.4.5.2. Japan Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.4.5.3. Japan Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026 (USD Million)
        • 8.4.6.2. India Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026 (USD Million)
        • 8.4.6.3. India Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026 (USD Million)
      • 8.4.7. Southeast Asia
        • 8.4.7.1. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.4.7.2. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.4.7.3. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.4.8.2. Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.4.8.3. Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
      • 8.5.2. Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by application, 2016 - 2026(USD Million)
      • 8.5.3. Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.5.4.2. Brazil Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.5.4.3. Brazil Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.5.5.2. Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.5.5.3. Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
      • 8.6.2. The Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by application, 2016 - 2026(USD Million)
      • 8.6.3. The Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.6.4. GCC Countries
        • 8.6.4.1. GCC Countries Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.6.4.2. GCC Countries Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.6.4.3. GCC Countries Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
      • 8.6.5. Rest of the Middle East and Africa
        • 8.6.5.1. Rest of the Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by product type, 2016 - 2026(USD Million)
        • 8.6.5.2. Rest of the Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by Application, 2016 - 2026(USD Million)
        • 8.6.5.3. Rest of the Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing market revenue, by End-User, 2016 - 2026(USD Million)
  • Chapter 9. Company Profile
    • 9.1. Vigene Biosciences Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Lonza
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. FinVector Vision Therapies
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Kaneka Corporation (Eurogentec)
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. XIFIN, Inc.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. VGXI, Inc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. VIROVEK
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. SIRION Biotech GmbH
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Cobra Biologics
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Novasep
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. FUJIFILM Diosynth Biotechnologies Inc.
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Product portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Spark Therapeutics, Inc.
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Product portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments
    • 9.13. Genzyme Corporation
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Product portfolio
      • 9.13.4. Business strategy
      • 9.13.5. Recent developments
    • 9.14. ALDEVRON
      • 9.14.1. Overview
      • 9.14.2. Financials
      • 9.14.3. Product portfolio
      • 9.14.4. Business strategy
      • 9.14.5. Recent developments
    • 9.15. Brammer Bio
      • 9.15.1. Overview
      • 9.15.2. Financials
      • 9.15.3. Product portfolio
      • 9.15.4. Business strategy
    • 9.16. General Electric Company (GE Healthcare)
      • 9.16.1. Overview
      • 9.16.2. Financials
      • 9.16.3. Product portfolio
      • 9.16.4. Business strategy
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll